Showing 1 - 2 results of 2 for search 'for the Antibacterial Resistance Leadership Group', query time: 0.02s Refine Results
  1. 1
    Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

    Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial by Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland, on behalf of the Antibacterial Resistance Leadership Group (ARLG)

    Published 2022-05-01
    Get full text
    Article
  2. 2
    Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

    Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized... by Pranita D. Tamma, Maria Souli, Michael Billard, Joseph Campbell, Douglas Conrad, Damon W. Ellison, Beth Evans, Scott R. Evans, Kerryl E. Greenwood-Quaintance, Andrey A. Filippov, Holly S. Geres, Toshimitsu Hamasaki, Lauren Komarow, Mikeljon P. Nikolich, Thomas P. Lodise, Seema U. Nayak, Carmelle Norice-Tra, Robin Patel, David Pride, Janie Russell, Daria Van Tyne, Henry F. Chambers, Vance G. FowlerJr, Robert T. Schooley, for the Antibacterial Resistance Leadership Group

    Published 2022-12-01
    Get full text
    Article

Search Tools: